<?xml version="1.0" encoding="UTF-8"?>
<p>For the 36 cases where treatment was described, 28 (78%) received intravenous immunoglobulin, 2 (6%) intravenous immunoglobulin and plasma exchange, 4 (11%) intravenous methylprednisolone, and 2 (6%) plasmapheresis. Forty (87%) of the 46 cases for whom follow‐up data were available improved. In some cases, this was rapid; in most, it had occurred by 3 months.</p>
